Next Pharmaceuticals’ Nexrutine To Be Studied, Forms Agreement With Wilke Resources

AMC Cancer Research Center, Denver, CO, has been awarded a two-year grant from the National Institutes of Health (NIH), Bethesda, MD, to study Nexrutine® as a prostate cancer preventative agent and to determine the molecular mechanism that underlies its efficacy. Nexrutine is a natural anti-inflammatory ingredient developed by Next Pharmaceuticals, Irvine, CA, for use in dietary supplements. It is a patent-pending plant extract from the bark of Phellodendron trees commonly found in Asia.

In other news, the company has entered into an agreement with Wilke Resources, Lenexa, KS, wherein Wilke will act as the exclusive U.S. sales agent for Next’s flagship products, Relora® and Nexrutine.